Skip to main content
Premium Trial:

Request an Annual Quote

CambridgeSoft Raises $21M, Names New VP

NEW YORK (GenomeWeb News) – Life science informatics developer CambridgeSoft said today that it has completed a $21 million private equity investment by Goldman Sachs.
 
In connection with the offering, Raheel Zia, a vice president at Goldman Sachs Principal Investment Area, will join CambridgeSoft's board of directors.
 
In addition, CambridgeSoft said that it has hired Michael Stapleton as vice president of corporate development, “with responsibilities for supporting the company's merger and acquisitions activities.”
 
Stapleton previously served as chief operating officer at Accelrys, where he was responsible for integrating Molecular Simulations, Synopsys, Oxford Molecular Group, and Genetics Computer Group under the Accelrys umbrella.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.